
ENERGENESIS — Investor Relations & Filings
Energenesis Biomedical Co., Ltd. specializes in the research and development of innovative pharmaceuticals through its proprietary ENERGI drug development platform. The company focuses on the activation of AMP-activated protein kinase (AMPK), a critical enzyme for cellular energy regulation, to develop therapeutic solutions for various diseases. Its core pipeline centers on small molecule purine compounds designed to modulate cellular energy metabolism. Operating with an intellectual property-driven strategy, the company manages the development cycle from early-stage drug discovery through clinical trial validation. Energenesis Biomedical aims to increase the value of its proprietary technologies for strategic out-licensing and collaboration with global pharmaceutical partners. In addition to drug development, the company offers specialized testing and analysis services and distributes research reagents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | |
| 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | |
| 115年第1季海外子公司投資 | 2026-05-11 | Chinese | |
| 115年第1季權益變動表 | 2026-05-11 | Chinese | |
| 115年第1季現金流量表 | 2026-05-11 | Chinese | |
| 115年第1季綜合損益表 | 2026-05-11 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46778242 | 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | ||
| 46338951 | 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | ||
| 45740777 | 115年第1季海外子公司投資 | 2026-05-11 | Chinese | ||
| 45746274 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741609 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741439 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741235 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 39978408 | 114年第4季財務報告書 — 202502_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871803 | 114年第4季財務報告書 — 202501_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871783 | 114年第4季財務報告書 — 202501_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886223 | 114年第4季財務報告書 — 202504_6657_AIC.pdf | 2026-04-30 | English | ||
| 39886197 | 114年第4季財務報告書 — 202504_6657_AIA.pdf | 2026-04-30 | English | ||
| 39886176 | 114年第4季財務報告書 — 202504_6657_AI3.pdf | 2026-04-30 | Chinese | ||
| 39886119 | 114年第4季財務報告書 — 202504_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886095 | 114年第4季財務報告書 — 202503_6657_AIA.pdf | 2026-04-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
FUNCTIONAL TECHNOLOGIES CORP.
Developed proprietary, advanced yeast-based solutions for t…
|
FEB | CA | Professional, scientific and te… |
|
FUSION ANTIBODIES PLC
CRO providing end-to-end services for preclinical antibody …
|
FAB | GB | Professional, scientific and te… |
|
GEMPHARMATECH CO., LTD.
Provides genetically engineered mouse models and preclinica…
|
688046 | CN | Professional, scientific and te… |
|
Genenta Science S.p.A.
Clinical-stage developer of hematopoietic stem cell gene th…
|
GNTA | IT | Professional, scientific and te… |
|
GeneOne Life Science, Inc.
Biopharmaceutical R&D company specializing in nucleic acid-…
|
011000 | KR | Professional, scientific and te… |
|
Generate Biomedicines, Inc.
Pioneering generative biology with an AI platform to create…
|
GENB | US | Professional, scientific and te… |
|
Geneuro
Develops therapies for neurological and autoimmune diseases…
|
GEM | CH | Professional, scientific and te… |
|
GENFIT
Develops therapies and diagnostics for patients with rare a…
|
GNFT | FR | Professional, scientific and te… |
|
GENFLOW BIOSCIENCES PLC
A biotechnology company developing gene therapies that targ…
|
GENF | GB | Professional, scientific and te… |
|
GENINCODE PLC
Specializes in genetic risk assessment and prediction of ca…
|
GENI | GB | Professional, scientific and te… |
ENERGENESIS via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52601/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52601 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52601 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52601 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52601}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ENERGENESIS (id: 52601)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.